Will the upward trend continue?

This success highlights the market’s demand for personalized weight management solutions that impact physical and emotional health. HIMS plans to further expand its weight loss offerings with the launch of liraglutide, the first generic GLP-1 drug, in 2025.

Expansion of the portfolio of personalized solutions

Personalization is the core value proposition for Hims & Hers and underpins its remarkable growth trajectory. In 2024, the company expanded its personalized solutions to all five core areas – mental health, sexual health, weight loss, dermatology and wellness. These solutions address individual needs through advanced AI-driven technologies and proprietary EMR systems and help providers create customized treatment plans. This approach resonates with consumers and encourages long-term subscriber loyalty.

In dermatology, for example, subscribers can choose between personalized sprays, serums or oral medications. This distinctive feature is aimed at a range of users, from those seeking preventative measures to those actively managing conditions such as hair loss or acne. Over 85% of dermatology subscribers opted for personalized solutions in Q2 2024, demonstrating the growing demand for such offerings.

Technology-driven customer loyalty

HIMS’ proprietary AI tools and machine learning capabilities play a critical role in delivering best-in-class customer experiences. MedMatch by Hims & Hers allows providers to customize medications, manage side effects and optimize treatment plans. Subscribers benefit from regular communication with their providers, an average of three times within the first four weeks of treatment. This level of personalized interaction improves compliance and promotes user trust and satisfaction.

Additionally, these technological advances reduce providers’ administrative burdens and allow them to focus more on patient care. This operational efficiency has become a cornerstone of Hims & Hers’ growth strategy.

HIMS Quarterly Sales and EPS Growth Chart

Image source: Zacks Investment Research

The weight loss category represents a significant growth opportunity given the prevalence of obesity-related health problems in the United States. Hims & Hers’ holistic approach to weight management, which includes both GLP-1 and oral solutions, addresses the physical and emotional aspects of obesity. The planned introduction of generic GLP-1 options and further advances in personalized care models are expected to further strengthen the company’s position in this important market segment.

HIMS is well positioned to expand its offering both geographically and into new disciplines. The company aims to increase the number of its subscribers many times over by 2030, supported by ongoing investments in its affiliated pharmacies and production capacities. The recent acquisition of an FDA-registered 503(b) facility should allow HIMS to expand into adjacent markets such as hormone therapy and complex compounded medications.

Plans include introducing more multi-condition solutions and expanding form factors such as chewables and gummies. These innovations aim to simplify treatments and improve adherence while maintaining affordability. By continuously adapting its offerings to changing consumer needs, the company is prepared for sustainable growth.

Democratizing healthcare remains a central pillar of HIMS’s long-term strategy. Leveraging its scale and technological capabilities, the company can offer personalized solutions at mass-market prices, ensuring access for underserved populations. This strategy has already shown results, with significant growth in subscribers from communities with average household incomes under $50,000.

HIMS stock is trading above its 50-day and 200-day moving averages

Image source: Zacks Investment Research

The personalized healthcare market is becoming increasingly competitive as established players and new entrants compete for market share. Competitors with strong brand recognition and more extensive resources may pose a threat to Hims & Hers’ growth. The HIMS share has performed significantly better than its competitors – Teladoc Health TDOC, LifeMD LFMD and American fountain AMWL – last month.

To stay at the forefront, the company must continue to innovate and differentiate itself from the competition through excellent customer experience and affordability. Although the company has achieved strong subscriber growth, maintaining customer retention rates and optimizing customer acquisition costs remain priorities. Continued investment in marketing and customer support will be critical to maintaining momentum.

As HIMS scales its operations, the company faces challenges related to maintaining supply chain integrity, managing costs and ensuring consistent quality. Investments in robotics and automation are expected to mitigate some of these risks, but implementation will be critical to sustainable growth. The regulatory landscape for telemedicine and GLP-1 drugs remains complex and unpredictable. Supply chain disruptions and shortages of branded GLP-1 drugs have created additional operational challenges. While Hims & Hers has mitigated some of these issues through compounding alternatives, the long-term impact of regulatory changes could impact its ability to scale certain offerings.

Hims & Hers Health is at the forefront of a paradigm shift in personalized healthcare. The company has established itself as a trusted provider of tailored healthcare solutions through innovation, technology and a commitment to affordability. While challenges such as regulatory pressures and competition remain, HIMS is positioned for long-term success based on its strong foundation and strategic vision. With ambitious growth plans, the company is poised to redefine the healthcare landscape and create lasting value for its customers and shareholders.

HIMS’s 1-month performance compared to competitors

Image source: Zacks Investment Research

HIMS currently has a Zacks Rank #3 (Hold). However, the style ratings look quite promising. Although the company has a Value Score of D, it has a Growth Score of A and a Momentum Score of B. Therefore, we believe investors could buy the stock now but remain cautious. Current shareholders should continue to hold their position and could benefit from further upside.

You can see You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Want the latest recommendations from Zacks Investment Research? Today you can download the 7 best stocks for the next 30 days. Click here to get this free report

Teladoc Health, Inc. (TDOC): Free Stock Analysis Report

American Well Corporation (AMWL): Free Stock Analysis Report

Hims & Hers Health, Inc. (HIMS): Free stock analysis report

LifeMD, Inc. (LFMD): Free stock analysis report

To read this article on Zacks.com click here.

Zacks Investment Research